Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Dimopoulou, I.
Right arrow Articles by Dimopoulos, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dimopoulou, I.
Right arrow Articles by Dimopoulos, M. A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:1250-1255, 2004
© 2004 European Society for Medical Oncology

A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment

Background: Small series and retrospective studies have suggested that treatment with gemcitabine may be associated with pulmonary toxicity. However, a prospective evaluation of cancer patients treated with gemcitabine-based chemotherapy without neoplastic involvement of the thorax and without administration of radiotherapy has not been performed.

Patients and methods: To investigate this issue, 41 consecutive patients receiving gemcitabine and carboplatin underwent prospective evaluation of lung function, which included pulmonary symptoms, pulmonary function tests, arterial blood gases and radiographic studies. Assessment was performed before and after completion of chemotherapy in all patients. Patients with a substantial decline in diffusion capacity for carbon monoxide (DLCO), defined as a drop of ≥20%, were reassessed 2 months later.

Results: After chemotherapy, there were no significant changes in forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), FEV1/FVC ratio, alveolar volume or total lung capacity. In contrast, there was a significant decline in DLCO (73±22 versus 67±24% predicted; P=0.017) and in carbon monoxide transfer coefficient (KCO) (89±24 versus 80±24% predicted; P=0.004). Arterial blood gases did not change following treatment. Ten of the 41 patients (24%) exhibited a substantial decline in DLCO, which, however, recovered within 2 months (DLCO at baseline, immediately after therapy and at 2 months after completion of treatment, 84±14, 58±16 and 77±17% predicted, respectively; P < 0.001; baseline DLCO versus DLCO at 2 months, P > 0.05). Four of the 41 patients (10%) experienced dyspnea, which was self-limiting, with the exception of one patient who developed interstitial lung fibrosis. Among the various risk factors examined, older age, female gender and lower baseline DLCO were associated with more profound changes in DLCO post-treatment.

Conclusions: This prospective analysis showed that the combination of gemcitabine and carboplatin induces a significant, but reversible, decrease in diffusion capacity, which is mostly asymptomatic. Thus, this regimen is safe as regards clinically significant lung toxicity.

I. Dimopoulou1,*, E. Efstathiou2, A. Samakovli1, U. Dafni3, L. A. Moulopoulos4, C. Papadimitriou2, P. Lyberopoulos1, E. Kastritis2, C. Roussos1 and M. A. Dimopoulos2

1 Department of Pulmonary & Critical Care Medicine, Evangelismos Hospital, Athens; 2 Department of Clinical Therapeutics, Alexandra Hospital, Athens; Departments of 3 Biostatistics and 4 Radiology, Areteion Hospital, Medical and Nursing School, National & Kapodistrian University of Athens, Athens, Greece

* Correspondence to: Dr I. Dimopoulou, 2 Pesmazoglou Street, 14 561 Kifissia, Athens, Greece. Tel: +301-210-6200-663; Fax: +301-210-6202-939; Email: idimo{at}otenet.gr

Key words: carboplatin, diffusion capacity for carbon monoxide, dyspnea, gemcitabine, lung toxicity, pulmonary function tests


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
ChestHome page
M. P. Rivera, F. C. Detterbeck, M. A. Socinski, D. T. Moore, M. J. Edelman, T. M. Jahan, R. H. Ansari, J. D. Luketich, G. Peng, M. Monberg, et al.
Impact of Preoperative Chemotherapy on Pulmonary Function Tests in Resectable Early-Stage Non-small Cell Lung Cancer
Chest, June 1, 2009; 135(6): 1588 - 1595.
[Abstract] [Full Text] [PDF]


Home page
Anticancer ResHome page
A. G. CHARPIDOU, I. GKIOZOS, S. TSIMPOUKIS, D. APOSTOLAKI, K. D. DILANA, E. M. KARAPANAGIOTOU, and K. N. SYRIGOS
Therapy-induced Toxicity of the Lungs: An Overview
Anticancer Res, February 1, 2009; 29(2): 631 - 639.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
R. S. Huang, E. O. Kistner, W. K. Bleibel, S. J. Shukla, and M. E. Dolan
Effect of population and gender on chemotherapeutic agent-induced cytotoxicity
Mol. Cancer Ther., January 1, 2007; 6(1): 31 - 36.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
I. Dimopoulou, A. Bamias, P. Lyberopoulos, and M. A. Dimopoulos
Pulmonary toxicity from novel antineoplastic agents
Ann. Onc., March 1, 2006; 17(3): 372 - 379.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.